Galapagos announces new collaboration with AstraZeneca
Advertisement
Galapagos NV announced that its service division BioFocus DPI has entered a new drug discovery collaboration with AstraZeneca. This collaboration marks the first time AstraZeneca has selected BioFocus DPI to provide drug discovery services. Under the terms of the agreement, BioFocus DPI will perform hit-to-lead medicinal chemistry services for AstraZeneca's respiratory and inflammatory drug discovery programs. Total contract value for Galapagos is EUR650,000.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
A Chip with Natural Blood Vessels - Create artificial blood vessels in miniature organ models in a rapid and reproducible manner
A Trojan horse for artificial amino acids - Researchers have modified a bacterial transport system so that it can efficiently introduce large quantities of unnatural amino acids into cells
New discoveries map out CRISPR-Cas defence systems in bacteria
CV Therapeutics Submits New Drug Application For Regadenoson
Chemicals in the environment: A focus on mixtures - Combined chemical and bioanalytical methods are able to efficiently characterise chemical mixtures
Italian field trial results suppressed - Data are relevant to human and animal health
Infraserv GmbH & Co. Höchst KG - Frankfurt am Main, Germany
MedGenome secures series C funding
Bringing cancer medication safely to its destination